Interestingly, today Reach Pharmaceuticals has announced that the TGA has granted dexrazoxane Orphan Designation in Australia.
Reach have 6 months now I believe to submit their registration dossier to the TGA for evaluation.
Whilst it doesn't have a direct impact on RAC I do find it interesting that the noise around cardio-oncology and cardioprotection is starting to be amplified globally. RAC couldn't be better positioned to become a global leader in this space. Looking forward to seeing how the team plan to execute on cardio-oncology in the new strategy.
Interestingly, today Reach Pharmaceuticals has announced that...
-
- There are more pages in this discussion • 304 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.80 |
Change
-0.025(1.37%) |
Mkt cap ! $306.5M | |||
| Open | High | Low | Value | Volume |
| $1.83 | $1.83 | $1.80 | $3.646K | 1.999K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 9476 | $1.79 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.83 | 280 | 1 |
View Market Depth
| Last trade - 10.15am 01/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |